Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma Academic Article uri icon

Overview

MeSH Major

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibiotics, Antineoplastic
  • Lymphoma, Non-Hodgkin

abstract

  • Elsamitrucin showed modest activity in patients with relapsed or refractory non-Hodgkin's lymphoma. Toxicity was relatively mild, consisted mainly of asthenia, nausea and vomiting and did not include myelosuppression. The activity of elsamitrucin in this group of patients and its lack of myelosuppression suggest utility in this disease especially when combined with other proven agents.

publication date

  • October 22, 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8913843

Additional Document Info

start page

  • 213

end page

  • 7

volume

  • 14

number

  • 2